Compare Ford Motor Company (F) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs State Street SPDR S&P Biotech ETF — how do they compare? Ford Motor Company trades at $13.98 (market cap $55.83B), while State Street SPDR S&P Biotech ETF trades at $158.17. The key difference: Ford Motor Company pays a 4.29% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Ford Motor Company nearer its low. Which is the better fit depends on your goals.
| F | XBI | |
|---|---|---|
Market Cap | $55.83B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $17.44 | $164.28 |
52-Week Low | $11.21 | $86.92 |
Enterprise Value | $187.79B | — |
Dividend Yield | 4.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford (F) trades at $13.98, up 1.38% with a bullish technical signal despite mixed fundamentals. The company reported negative net income of -$8.18B in 2025 but maintains strong operating cash flow of $21.28B. Recent news highlights Ford's new $28,350 Fathom EV truck launch for 2027, targeting affordable electric vehicles while managing EV transition costs through its profitable commercial Pro segment.
Outlook remains cautious with analyst consensus at $16.00 (43% buy ratings). Key opportunities include EV expansion and dividend stability ($0.15 quarterly), while risks involve persistent net losses, high debt levels (56.49% debt-to-asset), and competitive EV market pressures. The stock offers value with low P/E (11.84) but requires monitoring of profitability turnaround.
XBI, the SPDR S&P Biotech ETF, trades at $157.37, up 1.88% today, with a bullish technical signal from moving averages and strong momentum indicators. The ETF has surged nearly 17% in a month, driven by positive clinical trial news and increased M&A activity in the biotech sector. Analyst coverage is limited to one hold rating, reflecting cautious optimism amid high volatility.
Outlook remains positive due to sector tailwinds like AI-driven drug discovery and robust M&A, but risks include policy uncertainty and the fund's high beta. Investors should weigh the potential for continued growth against inherent volatility in small- and mid-cap biotech holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
